Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

EGFR tyrosine kinase inhibitor (TKI) vs observation

Overall survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

EGFR tyrosine kinase inhibitor (TKI) showed no clear difference in overall survival compared with observation alone (low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 0.99 [0.81, 1.2]
1 study · 835 participants
Low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Progression‐free survival · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) changes progression‐free survival compared with observation alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
HR 1.05 [0.9, 1.23]
1 study · 835 participants
Very low

EGFR tyrosine kinase inhibitor (TKI) vs observation

Quality of life · maintenance treatment of epithelial ovarian cancer after first‐line chemotherapy

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 835 participants
Very low